Dimension Capital

Stately Bio is a biotechnology company that specializes in live-cell imaging technology. It utilizes patented machine learning methods to analyze cell identity, behavior, and maturation without the need for labels, allowing for real-time observation of living cells. By focusing on the balance between accurate measurement and cellular viability, Stately Bio aims to advance research and applications in cellular biology. Currently, the company operates in stealth mode, suggesting that it is in the early stages of development and may be preparing for future product launches or partnerships.

Achira, a biotechnology company, specializes in accelerating drug discovery by combining artificial intelligence and physics-based simulations. It develops high-fidelity, scalable models for molecular dynamics, generating synthetic data to enhance drug discovery processes. By addressing the scarcity and high cost of drug discovery data, Achira's atomistic foundation simulation models enable clients to identify and develop therapeutic compounds more efficiently.

Aspect Biosystems Ltd. is a biotechnology company based in Vancouver, Canada, specializing in 3D bioprinting and tissue engineering. Founded in 2013, the company leverages proprietary microfluidic 3D bioprinting technology to develop bioprinted tissue therapeutics aimed at transforming disease treatment. By integrating therapeutic cells and materials science, Aspect Biosystems creates allogeneic cell-based tissue therapeutics that can replace or repair damaged organ functions. The company also provides a Lab-on-a-printer technology that allows precise control over biomaterial composition and structure during tissue fabrication. Its innovative platform supports the development of novel therapeutics and enhances understanding in fundamental biology and disease research, catering to pharmaceutical firms and academic institutions focused on respiratory diseases and regenerative medicine. Aspect Biosystems is actively collaborating with researchers and industry leaders to address significant challenges in the field of regenerative medicine.

KimiaTherapeutics is a drug discovery business that uses high throughput precision chemistry in conjunction with genome editing and machine learning to uncover druggable sites at crucial nodes of intervention in human disease.

Automata is an automation company focused on providing robotic solutions for the life sciences sector. It specializes in developing simple and affordable robotic devices designed to enhance laboratory efficiency and accelerate innovation. By offering robotic automation to labs, Automata enables organizations to scale operations and achieve results more quickly. The company's technology allows for seamless reconfiguration of tasks, making it accessible for professionals in various environments, including labs, classrooms, and production lines. This flexibility ensures that businesses can easily adapt their robotic systems to meet evolving needs, facilitating greater productivity and collaboration in scientific research and manufacturing.

NewLimit is a biotechnology company focused on addressing age-related diseases to enhance the human health span. It is engaged in the development of epigenetic reprogramming therapies aimed at reversing the aging process and improving life expectancy. By utilizing advanced techniques such as single-cell sequencing, NewLimit aims to rejuvenate tissue across the entire body, targeting diseases that currently have significant unmet medical needs. Through its innovative approach, the company seeks to provide effective solutions for extending health and vitality in aging populations.

Enveda Biosciences is a biotechnology company that employs artificial intelligence-powered tools to investigate and define molecules sourced from living organisms. Its primary objective is to build an exhaustive database of chemical biodiversity, thereby expediting the discovery of novel medicines. The company's innovative drug discovery platform integrates machine learning, metabolomics, and robotics to analyze natural samples for both chemical structure and biological activity, eliminating the need for isolating individual compounds or extensive experimentation. This enables healthcare industry clients to develop a wide range of new medications, from antibiotics to hypotensives.

Enveda Biosciences is a biotechnology company that employs artificial intelligence-powered tools to investigate and define molecules sourced from living organisms. Its primary objective is to build an exhaustive database of chemical biodiversity, thereby expediting the discovery of novel medicines. The company's innovative drug discovery platform integrates machine learning, metabolomics, and robotics to analyze natural samples for both chemical structure and biological activity, eliminating the need for isolating individual compounds or extensive experimentation. This enables healthcare industry clients to develop a wide range of new medications, from antibiotics to hypotensives.

Kaleidoscope is a collaborative, cloud-based research platform for organizing and tracking scientific activities.

Lamin Labs is a Munich-based company founded in 2022 that focuses on providing data infrastructure for the field of biology. The company aims to enhance collaboration among data scientists and engineers by creating a unified data layer for research and development teams, regardless of size. By integrating various aspects of laboratory work, including wet and dry laboratories, artificial intelligence, and knowledge management, Lamin Labs seeks to streamline the management of biological data and analyses. Its innovative data application programming interfaces utilize machine learning algorithms to facilitate data analysis and management services, thereby supporting the biotechnology industry in effectively handling complex biological data.

NewLimit is a biotechnology company focused on addressing age-related diseases to enhance the human health span. It is engaged in the development of epigenetic reprogramming therapies aimed at reversing the aging process and improving life expectancy. By utilizing advanced techniques such as single-cell sequencing, NewLimit aims to rejuvenate tissue across the entire body, targeting diseases that currently have significant unmet medical needs. Through its innovative approach, the company seeks to provide effective solutions for extending health and vitality in aging populations.

Verisian is a technology company that specializes in accelerating drug development and approval processes. It offers a data platform designed for health professionals, which enhances trial integrity and traceability, enabling real-time analysis and monitoring of studies. This platform ultimately helps to bring safe and effective therapies to patients faster by streamlining the drug testing and FDA approval process.